Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cambrex boosts small molecules in North Carolina

by Rick Mullin
October 15, 2021 | A version of this story appeared in Volume 99, Issue 38

 

Citing growing demand for small-molecule drug services, Cambrex says it will spend over $30 million to expand its plant in High Point, North Carolina. The company plans to add two clinical-scale manufacturing suites and a commercial-scale operation with 2,000 L reactors. It will also establish a 500 kg per year facility for orphan drugs and niche therapies. The projects will add 78 jobs at the site. Cambrex got the High Point plant in its acquisition of PharmaCore in 2016.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.